Abstract
Herein, two new p-cymene ruthenium(II) complexes [(eta(6)-p-cymene)Ru (L1-OH) Cl] 1 and [(eta(6)-p-cymene)Ru(L-2-OH)Cl] 2 of thiazolyl-derived ligands i.e., (E)-2-(((5-methylthiazol-2-yl) imino) methyl) phenol (L-1) and (E)-4-methyl-2-((5-methylthiazol-2-yl)imino) methyl)phenol (L-2) have been designed and synthesized. The FT-IR, (HNMR)-H-1, C-13 NMR spectroscopy and elemental analysis characterized both the ligands and the complexes. The representative molecular structures of the ligand L-2 and complex 1 were determined by single X-ray crystallography. Moreover, the DFT studies were carried out to optimize the geometries and calculate the energies of the molecules by frontier molecular orbitals. Using multi-spectroscopic techniques and computational studies, these ruthenium arenes complexes 1 and 2 were investigated for the binding affinity towards human serum albumin (HSA). The results revealed the significantly good binding propensity of these complexes 1 and 2 towards HSA. The intrinsic binding studies exhibited the decerase in stern-volmer constant (Ksv) with increase in temperature. The mode of binding was also found to be static. The results obtained from extrinsic flouresence using ANS dye, ascertained the competitive binding inducing conformational alterations of HSA. Furrthermore, The cytotoxicity results displayed good IC50 values against HeLa cells compared to cisplatin, which is suggestive of the anti-cancer chemotherapeutic potential of complexes.